Morgan Stanley’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-10,295,665
Closed -$5.97M 8208
2024
Q3
$5.97M Buy
10,295,665
+5,841,638
+131% +$3.27M ﹤0.01% 3832
2024
Q2
$2.75M Sell
4,454,027
-2,287,863
-34% -$1.93M ﹤0.01% 4345
2024
Q1
$17.3M Sell
6,741,890
-4,299,016
-39% -$10.5M ﹤0.01% 2858
2023
Q4
$22.5M Buy
11,040,906
+9,278,665
+527% +$16.9M ﹤0.01% 3227
2023
Q3
$3.03M Sell
1,762,241
-15,185
-0.9% -$27K ﹤0.01% 4089
2023
Q2
$3.47M Sell
1,777,426
-55,199
-3% -$129K ﹤0.01% 4037
2023
Q1
$5.09M Sell
1,832,625
-159,854
-8% -$457K ﹤0.01% 3778
2022
Q4
$6.87M Sell
1,992,479
-63,828
-3% -$182K ﹤0.01% 3456
2022
Q3
$5.29M Buy
2,056,307
+768,500
+60% +$2.45M ﹤0.01% 3642
2022
Q2
$3.12M Buy
1,287,807
+1,093,446
+563% +$2.87M ﹤0.01% 4171
2022
Q1
$801K Buy
194,361
+160,309
+471% +$849K ﹤0.01% 5126
2021
Q4
$437K Sell
34,052
-7,789
-19% -$86.3K ﹤0.01% 5623
2021
Q3
$451K Sell
41,841
-19,084
-31% -$174K ﹤0.01% 5561
2021
Q2
$556K Sell
60,925
-1,338,583
-96% -$12.4M ﹤0.01% 5463
2021
Q1
$13.2M Buy
1,399,508
+1,090,080
+352% +$15M ﹤0.01% 2364
2020
Q4
$1.22M Buy
309,428
+306,707
+11,272% +$928K ﹤0.01% 4542
2020
Q3
$7K Sell
2,721
-137,976
-98% -$512K ﹤0.01% 6379
2020
Q2
$935K Buy
140,697
+137,769
+4,705% +$928K ﹤0.01% 4233
2020
Q1
$17K Sell
2,928
-30,530
-91% -$256K ﹤0.01% 5871
2019
Q4
$300K Buy
33,458
+26,669
+393% +$222K ﹤0.01% 5217
2019
Q3
$59K Buy
6,789
+6,136
+940% +$62K ﹤0.01% 5650
2019
Q2
$7K Sell
653
-658
-50% -$7.53K ﹤0.01% 6241
2019
Q1
$17K Sell
1,311
-9,293
-88% -$124K ﹤0.01% 6060
2018
Q4
$164K Buy
+10,604
New +$202K ﹤0.01% 5362

Other funds holding GRTS

Morgan Stanley's GRTS Position: Q4 2024 in Review

Morgan Stanley sold out of Gritstone bio, Inc. Common Stock (GRTS) in Q4 2024, closing a stake of 10,295,665 shares — an estimated $5.97M sold.

Morgan Stanley first reported a position in GRTS in Q4 2018 and held it in 24 quarters. The position peaked at $22.5M in Q4 2023. 6 funds tracked by Wall St. Rank hold GRTS as of Q4 2024.

  • Morgan Stanley reported no remaining Gritstone bio, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Morgan Stanley sold 10,295,665 Gritstone bio, Inc. Common Stock shares in Q4 2024, an estimated $5.97M.
  • Morgan Stanley first reported a position in Gritstone bio, Inc. Common Stock in Q4 2018 and held it in 24 quarters.
  • Morgan Stanley's Gritstone bio, Inc. Common Stock position peaked at $22.5M in Q4 2023.
  • 6 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q4 2024.

Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.